AbbVie has filed a new-drug application with the FDA by for glecaprevir/pibrentasvir, a pan-genotypic regimen intended to treat chronic hepatitis C virus. The filing was backed by data from eight registrational studies included in the drug’s clinical development program spanning 27 countries.